Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$78 Mln
P/E Ratio
--
P/B Ratio
1.02
Industry P/E
--
Debt to Equity
0.01
ROE
-0.75 %
ROCE
-74.48 %
Div. Yield
0 %
Book Value
2.64
EPS
-2.4
CFO
$-133.94 Mln
EBITDA
$-170.35 Mln
Net Profit
$-162.36 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Aerovate Therapeutics Inc (AVTE)
| 3.77 | 11.34 | 13.17 | -88.36 | -45.34 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Aerovate Therapeutics Inc (AVTE)
| -88.08 | -22.76 | 148.52 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Address:... 930 Winter Street, Waltham, MA, United States, 02451 Read more
CEO & Director
Mr. Timothy P. Noyes M.B.A.
CEO & Director
Mr. Timothy P. Noyes M.B.A.
Headquarters
Waltham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Aerovate Therapeutics Inc (AVTE) stood at $ 80 Mln as on 31-Dec-24
The share price of Aerovate Therapeutics Inc (AVTE) is $2.75 (NASDAQ) as of 17-Apr-2025 16:08 EDT. Aerovate Therapeutics Inc (AVTE) has given a return of -45.34% in the last 3 years.
Aerovate Therapeutics Inc (AVTE) has a market capitalisation of $ 78 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Aerovate Therapeutics Inc (AVTE) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Aerovate Therapeutics Inc (AVTE) and enter the required number of quantities and click on buy to purchase the shares of Aerovate Therapeutics Inc (AVTE).
Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Address: 930 Winter Street, Waltham, MA, United States, 02451
The CEO & director of Mr. Timothy P. Noyes M.B.A.. is Aerovate Therapeutics Inc (AVTE), and CFO & Sr. VP is Mr. Timothy P. Noyes M.B.A..
There is no promoter pledging in Aerovate Therapeutics Inc (AVTE).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Aerovate Therapeutics Inc (AVTE) | Ratios |
|---|---|
|
Return on equity(%)
|
-74.91
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Aerovate Therapeutics Inc (AVTE) was $0 Mln.
$0.07
(
